Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.
Mader, Julia K
Pieber, Thomas R
Journal of diabetes science and technology
Diabetes Technology Society
MetadataShow full item record
Leelarathna, L., Thabit, H., Wilinska, M., Bally, L., Mader, J. K., Pieber, T. R., Benesch, C., et al. (2020). Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.. Journal of diabetes science and technology, 14 (2), 277-283. https://doi.org/10.1177/1932296819838525
Real-time continuous glucose monitoring (CGM) and intermittently viewed continuous glucose monitoring has transformed the management of type 1 diabetes (1) and paved the way to novel therapeutic interventions such as automated insulin delivery (2). Usage of real-time CGM by multiple daily injection (MDI) users has been shown to improve HbA1c (3) and reduce the burden of hypoglycaemia (4). There is increasing recognition of the limitations of HbA1c as the sole measure of glycaemic control, as it provides little or no information on clinically relevant outcomes such as hypoglycaemia or glucose variability (5-6). In contrast, continuous glucose monitoring (CGM) data provide detailed information about multiple aspects of glucose control such as time spent in the target glucose range (TIR), time spent in hypo and hyperglycaemia as well as glucose variability (GV). An international panel of experts has recently agreed on reporting of various CGM based metrics under research and clinical care setting (7).
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
External DOI: https://doi.org/10.1177/1932296819838525
This record's URL: https://www.repository.cam.ac.uk/handle/1810/289667